WST — West Pharmaceutical Services, Inc. stock price, charts and financials

QT64West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. (NYSE: WST) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
348.76
+0.82+0.24%
OverviewShort InterestFilings
WSTQT64West Pharmaceutical Services, Inc.·NYSE
348.76+0.24%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MDLN+3.88%$42.04SOLV-0.15%$87.94BAX+0.89%$28.35COO+0.62%$74.69BDX-0.05%$170.12AVTR+0.07%$13.68ATR-0.43%$136.18RGEN+1.85%$149.78
Snapshot
IndexS&P 500P/E44.49EPS (ttm)7.82Insider Own0.99%Shs Outstand70.38MPerf Week5.04%
Market Cap24.49BForward P/E34.96EPS next Y9.95Insider Trans-0.54%Shs Float69.93MPerf Month-4.87%
Enterprise Value24.36BPEG3.74EPS next Q2.18Inst Own-Short Float3.38%Perf Quarter15.72%
Income565.00MP/S7.36EPS this Y14.36%Inst Trans-Short Ratio2.80Perf Half Y50.55%
Sales3.33BP/B8.19EPS next Y11.29%ROA13.86%Short Interest2.36MPerf YTD26.46%
Book/sh42.49P/C56.16EPS next 5Y11.88%ROE18.51%52W High386.91 -9.86%Perf Year45.42%
Cash/sh6.20P/FCF54.92EPS past 3/5Y-4.18% 8.27%ROIC15.77%52W Low224.36 55.45%Perf 3Y-1.96%
Dividend Est.0.88 (0.25%)EV/EBITDA29.53Sales past 3/5Y2.13% 7.44%Gross Margin36.77%Volatility2.21% 2.88%Perf 5Y-7.83%
Dividend TTM0.88 (0.25%)EV/Sales7.32EPS Y/Y TTM16.89%Oper. Margin20.64%ATR (14)10.38Perf 10Y345.96%
Dividend Ex-DateJul 29, 2026Quick Ratio2.12Sales Y/Y TTM14.97%Profit Margin16.98%RSI (14)52.52Recom2.33
Dividend Gr. 3/5Y5.20% 5.51%Current Ratio2.82EPS Q/Q28.80%SMA20-0.67%Beta1.11Target Price372.13
Payout11.05%Debt/Eq0.13Sales Q/Q13.84%SMA502.63%Rel Volume0.79Prev Close347.94
Employees10,800LT Debt/Eq0.12EarningsOct 22SMA20021.94%Avg Volume814.49KPrice348.76
IPO DateMar 17, 1980Option/ShortYes / YesEPS/Sales Surpr.13.86% 3.85%Net Debt/EBITDA-0.15Volume643,101Change0.24%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-27-26ReiteratedEvercore ISI GroupOutperform$410 → $425
Jul-13-26InitiatedBNP ParibasOutperform$447
Jul-09-26ReiteratedMorgan StanleyEqual Weight$315 → $365
Jul-06-26ReiteratedEvercore ISI GroupOutperform$320 → $410
Jul-02-26ReiteratedKeybancOverweight$390
Jun-09-26UpgradeBarclaysEqual Weight → Overweight$310 → $400
Apr-27-26ReiteratedMorgan Stanley$285 → $315
Apr-27-26ReiteratedBarclaysEqual Weight$265 → $310
Feb-13-26ReiteratedUBSBuy$355 → $340
Feb-13-26ReiteratedDeutsche BankHold$310 → $315
Latest News
Aug-03-26
Aug-03-2602:52PM
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412Benzinga
Jul-31-26
Jul-31-2608:38AM
Conestoga SMid Cap Composite Q2 2026 Portfolio Reviewseekingalpha.com
Jul-29-26
Jul-29-2603:37AM
West Pharmaceutical Services, Inc. $WST Holdings Increased by Dimensional Fund Advisors LPdefenseworld.net
Jul-27-26
Jul-27-2601:24PM
MMED Gets Medicare Coverage for Flex and Broadens Diabetes Care AccessYahoo
Jul-26-26
Jul-26-2603:57AM
West Pharmaceutical Services, Inc. $WST Shares Acquired by Bank of Nova Scotiadefenseworld.net
Jul-24-26
Jul-24-2608:08AM
West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shiftseekingalpha.com
Jul-23-26
Jul-23-2611:04PM
West Pharmaceutical Services Q2 Earnings Call Highlightsmarketbeat.com
03:11PM
WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growthzacks.com
11:40AM
West Pharmaceutical Services, Inc. (WST) Q2 2026 Earnings Call Transcriptseekingalpha.com
11:32AM
West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentumbenzinga.com
10:31AM
West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com
08:16AM
West Pharmaceutical Services (WST) Q2 Earnings and Revenues Top Estimateszacks.com
06:33AM
West Pharmaceutical raises annual profit forecast on strong demand for injectable drug componentsreuters.com
06:00AM
West Reports Second-Quarter 2026 Resultsprnewswire.com
Jul-22-26
Jul-22-2603:45AM
Andra AP fonden Has $13.79 Million Stake in West Pharmaceutical Services, Inc. $WSTdefenseworld.net
Company

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,3263,0742,8932,9512,8862,8312,1471,8441,718
Cost of Goods Sold Incl. D&A2,1041,9701,8911,8181,7471,6571,3791,2351,172
Gross Profit1,2231,1031,0021,1331,1391,173768609546
Selling, General and Administrative Excl. Other428393339353317362302273263
Research and Development757469685953473940
Other Operating Expense331901-1000-11
Operating Income687617595711764759419297255
Interest Expense013989988
Unusual Expense
—————————
Non-Operating Income (Expense)13-1914-55198122
Net Income Before Taxes699615600716701769419301248
Income Taxes144122108122115107735941
Consolidated Net Income565494493593586662346242207
Net Income From Continuing Operations555494493593586662346242207
Net Income565494493593586662346242207
EPS (Recurring)7.876.836.757.997.888.904.683.272.80
EPS (Basic, Before Extraordinaries)7.876.836.757.997.888.904.683.272.80
EPS (Diluted)7.826.806.697.887.738.674.573.212.74
EBITDA825724744844808880519403353
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio44.6040.4648.9644.6930.4554.1061.9946.8335.78
Price To Sales Ratio7.446.448.278.836.0312.269.766.034.22
Gross Margin36.7735.8834.6438.3939.4741.4335.7733.0331.78
Operating Margin20.6620.0720.5724.0926.4726.8119.5216.1114.84
Net Margin16.9916.0717.0420.0920.3023.3816.1213.1212.05
Shares Outstanding717273747474747474
Market Capitalization24,76219,81023,91226,05717,41634,70720,96511,1247,254
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$389.76$337.71$285.66$233.62$181.57● Close Price0.00M0.28M0.56M0.85M1.13MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Campbell Shane AldenSVP, Proprietary SegmentMay 12 '26Option Exercise0.007700748May 14
Favorite Annette FSr. VP & Chief HR OfficerApr 27 '26Sale305.202,817859,75316,828Apr 29
Winters ChadVP, Chief Accounting OfficerApr 27 '26Option Exercise173.22896155,2052,419Apr 29
Winters ChadVP, Chief Accounting OfficerApr 27 '26Sale300.67896269,3991,523Apr 29
Favorite Annette FSr. VP & Chief HR OfficerApr 27 '26Option Exercise83.472,817235,13519,645Apr 29
Poussot Rodolphe JeanSVP, Strategy & Corporate DevFeb 20 '26Option Exercise0.003830691Feb 23
Witherspoon CharlesVP & TreasurerFeb 20 '26Option Exercise0.006001,430Feb 23
Winters ChadVP, Chief Accounting OfficerFeb 20 '26Option Exercise0.008901,553Feb 23
Poussot Rodolphe JeanSVP, Strategy & Corporate DevFeb 18 '26Option Exercise0.00820335Feb 19
Green Eric MarkPresident, CEO and Board ChairFeb 18 '26Option Exercise0.001,3190175,734Feb 19
Favorite Annette FSr. VP & Chief HR OfficerFeb 18 '26Option Exercise0.00135017,410Feb 19
McMahon Robert W.SVP & Chief Financial OfficerFeb 11 '26Option Exercise0.004,23104,231Feb 12
Birkett BernardSr VP, Chief Financial OfficerFeb 18 '25Option Exercise211.00904190,8137,669Feb 20
Reiss-Clark CindyChief Commercial OfficerFeb 18 '25Option Exercise211.0024651,9405,131Feb 20
MacKay Kimberly BanksSVP, GC & Corporate SecretaryFeb 18 '25Option Exercise211.0024651,9401,605Feb 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.